Magle Chemoswed Holding Reports Financial Results For Third Quarter 2023
Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.
Q3 2023 KEY INDICATORS
- Net sales amounted to 36.3 MSEK (34.1)
- EBITDA equalled 4.8 MSEK (4.8)
- Operating profit (EBIT) is 1.5 MSEK (1.4)
- Profit after tax amounted to 0.5 MSEK (1.2)
- Earnings per share SEK 0,1 (0,1) per share
JAN-SEPT 2023 KEY INDICATORS
- Net sales amounted to 113.1 MSEK (99.8)
- EBITDA equalled 21.8 MSEK (20.1)
- Operating profit (EBIT) is 12.1 MSEK (10.1)
- Profit after tax amounted to 8.1 MSEK (9.1)
- Earnings per share SEK 0,8 (0,8) per share
“Magle Group has made yet another strong quarter, both in terms of revenue and profit. Total revenues from our CDMO business and DSM-based products increased by 6.7% percent compared to last year’s corresponding period, which is well within our expectations. During the quarter, we have taken a major step in our commercialization strategy by signing a worldwide distribution agreement with the global medical device company, Sirtex Medical” says Justin Pierce, CEO
The full report is available at https://maglegroup.com/financial-reports/
